Biography

Kelly Stinson is the mycobacteriology development lead for the TB Drugs portfolio at the Gates Medical Research Institute, overseeing assessments of investigational agents and combination regimens. She brings 16 years of microbiology leadership in clinical development, including serving as microbiology lead at Otsuka Pharmaceuticals for the successful delamanid program for MDR-TB. She later founded Cultura, Inc., a consulting firm supporting TB clinical research. Earlier, she worked as a senior clinical research associate on delamanid and as a staff epidemiologist in CDC’s TB division. She holds an MPH from Emory University and a BS in Biology from Georgia State University.